Dynamic ctDNA Monitoring in Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma Clinical Trial

— ctDNA  

Official title:

A Study on Dynamic Monitoring of ctDNA in Neoadjuvant Therapy With Cetuximab Combined With Albumin-bound Paclitaxel and Nedaplatin for Esophageal Squamous Cell Carcinoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06103890
• Other study ID #: NATEC
• Status: Recruiting
• Start date: May 22, 2023
• Est. completion date: July 31, 2025

Study information

• Verified date: October 2023
• Source: Hebei Medical University Fourth Hospital
• Contact: Ziqiang Tian, MD
• Phone: 18531118000
• Email: tianzq1026[@]163.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study is a prospective, multicenter, open-label, observational cohort study. The primary endpoint is pathological complete response (pCR), and the secondary endpoints include R0 resection rate, ctDNA clearance rate, major pathological response (MPR), recurrence-free survival (RFS), and overall survival (OS). Chinese patients with esophageal squamous cell carcinoma who are eligible for surgical resection will receive neoadjuvant therapy with cetuximab combined with albumin-bound paclitaxel and nedaplatin. Personalized ctDNA monitoring will be conducted at multiple time points, including before neoadjuvant therapy, during therapy, preoperatively, postoperatively, and during adjuvant therapy, to explore the clinical value of minimal residual disease (MRD) as a biomarker for assessing treatment efficacy, predicting recurrence risk, and evaluating prognosis in esophageal squamous cell carcinoma. This study aims to enroll 100 Chinese patients with stage II-III (potentially) resectable esophageal squamous cell carcinoma.

Description:

This study aims to enroll 100 Chinese patients with stage II-III (potentially) resectable esophageal squamous cell carcinoma.

Tumor tissue samples will be collected from the subjects before neoadjuvant therapy for whole-exome sequencing (WES). Based on the WES results, personalized ctDNA detection panels will be designed (referred to as panel 1) for blood-based multiplex PCR-NGS testing. Blood samples will be collected at baseline (T0), after the first cycle of treatment (T1), after the second cycle of treatment (T2), after the third cycle of treatment (T3), and after the fourth cycle of treatment (T4) for monitoring.

Intraoperative tumor tissue will be collected. For patients with tumor cell content ≥20%, WES will be performed, and a personalized ctDNA detection panel (referred to as panel 2) will be designed based on the WES results. For patients with tumor cell content <20%, panel 1 will continue to be used for blood-based multiplex PCR-NGS testing. Blood samples will be collected before surgery (T5), 3-7 days after surgery (T6), and during the adjuvant therapy period (T7-TN) for ctDNA monitoring. MRD monitoring will be conducted every 3-6 months during follow-up, with dynamic recurrence monitoring until radiological recurrence or the end of the study. The stable detection limit for ctDNA monitoring is 0.02%.

It is expected to complete enrollment within 1 year. Clinical and pathological data, such as performance status, imaging, and serum markers (e.g., CEA), will be collected during the clinical trial. Follow-up will be conducted for 24 months, and data on treatment regimens, recurrence-free survival (RFS), overall survival (OS), adverse events (AE), etc., will be collected. Continuous observation will be conducted for up to 3 years.

Bioinformatics analysis will be performed on the data to construct mutation profiles. Statistical analysis will be conducted to establish the correlation between ctDNA positivity, mutation characteristics, and prognostic indicators. The ctDNA data analysis results will be linked to clinical management to ultimately improve clinical care.

Treatment regimen: Neoadjuvant therapy with cetuximab combined with albumin-bound paclitaxel and nedaplatin for 2-4 cycles:

Albumin-bound paclitaxel: 400mg, IV, on day 1, every 3 weeks; Nedaplatin: 80 mg/m2, IV, every 3 weeks; Cetuximab: 200mg, IV, on day 1, every 3 weeks.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: July 31, 2025
• Est. primary completion date: June 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Age between 18 and 70 years, regardless of gender.

2. Patients with histologically confirmed clinical stage II-III thoracic esophageal squamous cell carcinoma.

3. Neck enhanced CT scan showing no suspicious lymph node metastasis in the neck; no systemic metastasis detected by imaging examination.

4. Expected to achieve R0 resection.

5. ECOG performance status of 0-1.

6. No prior anti-tumor treatment for esophageal cancer, including chemotherapy, radiotherapy (including planned radiotherapy during the study period), hormone therapy, and immunotherapy.

7. Measurable lesions (according to RECIST v1.1 criteria).

8. Preoperative evaluation of organ function shows no contraindications for surgery.

9. Laboratory tests confirm good bone marrow, liver, kidney function, and coagulation function.

10. Able to provide informed consent and willing to cooperate with clinical follow-up.

11. Willing to provide peripheral blood samples for testing, as well as the patient's medical history, current treatment information, imaging studies, and tumor marker data, and willing to use the testing data for further scientific research, clinical diagnosis and treatment, and commercial product development.

Exclusion Criteria:

1. Unable to provide a sufficient amount of tissue samples/blood samples required for the study before treatment.

2. Patient refuses to undergo MRD testing.

3. History of malignancies other than esophageal cancer within the past 5 years (excluding cured localized tumors, such as cervical carcinoma in situ, basal cell carcinoma, and prostate carcinoma in situ; patients with prostate cancer who have received hormone therapy and achieved disease-free survival for more than 5 years are not excluded).

4. History of gastrointestinal bleeding within the past 6 months, or presence of coagulation abnormalities at enrollment, or currently receiving thrombolytic or anticoagulant therapy, indicating a high risk of bleeding.

5. Severe cardiovascular or cerebrovascular diseases.

6. History of interstitial lung disease or active pneumonia requiring steroid treatment at enrollment.

7. Active tuberculosis at enrollment or received anti-tuberculosis treatment within the past year.

8. Bronchial asthma requiring intermittent use of bronchodilators or other medical interventions at enrollment.

9. Presence of systemic infectious diseases requiring systemic treatment within the past 4 weeks at enrollment.

10. Severe unhealed wounds, active ulcers, or untreated fractures at enrollment.

11. Presence of other non-surgical conditions.

12. Previous surgeries that prevent the use of gastric conduit for esophageal reconstruction.

13. Severe allergic reactions to chemotherapy drugs (such as paclitaxel, albumin-bound paclitaxel, cisplatin, or carboplatin) or any monoclonal antibody.

14. History of organ transplantation.

15. Other conditions deemed unsuitable for participation in this study according to the investigator's judgment.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Squamous Cell
• Esophageal Squamous Cell Carcinoma

Locations

Country	Name	City	State
China	Department of Thoracic Surgery, Fourth Hospital of Hebei Medical University	Shijiazhuang	Hebei

Sponsors (3)

Lead Sponsor	Collaborator
Hebei Medical University Fourth Hospital	Handan Central Hospital, Xingtai People's Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	pCR	pCR stands for pathological complete response. It refers to the absence of any detectable cancer cells in the tissue sample taken during surgery after neoadjuvant treatment.	Up to 1 year
Secondary	R0 resection rate	The R0 resection rate refers to the rate of complete tumor removal without any residual tumor cells in the surgical specimen after neoadjuvant treatment.	Up to 1 year
Secondary	ctDNA clearance rate	The ctDNA clearance rate refers to the extent of elimination of circulating tumor DNA (ctDNA) during neoadjuvant treatment. It is evaluated by comparing the levels of ctDNA before and after neoadjuvant therapy to assess the impact of treatment on the tumor.	Up to 1 year
Secondary	MPR	MPR stands for Major Pathological Response. It refers to a significant reduction or disappearance of tumor cells in the surgical specimen after neoadjuvant therapy.	Up to 1 year
Secondary	RFS	RFS stands for Recurrence-Free Survival. It refers to the length of time after curative surgery following neoadjuvant treatment during which a patient remains free from any signs or symptoms of cancer recurrence.	3 years
Secondary	OS	OS stands for Overall Survival. It refers to the length of time from the start of neoadjuvant treatment to the death of a patient from any cause.	3 years